During the past decade, ISPG - Institut fuer Studien zur Psychischen Gesundheit conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" #1 sponsor was "Biogen" with 3 trials, followed by "AstraZeneca" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored, "FUJIFILM Toyama Chemical Co., Ltd." with 1 trials sponsored and "Vivoryon Therapeutics N.V." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" #1 collaborator was "Amsterdam UMC, location VUmc" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Nordic Bioscience A/S" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" are "Alzheimer's Disease" (4 trials), "Alzheimer Disease" (1 trials), "Brain Diseases" (1 trials), "Central Nervous System Diseases" (1 trials) and "Dementia" (1 trials). Many other conditions were trialed in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" in a lesser frequency.

Most popular intervention types in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" are "Drug" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Aducanumab" (1 trials), "Aducanumab (BIIB037)" (1 trials), "BIIB092" (1 trials) and "Donanemab" (1 trials). Other intervention names were less common.

The vast majority of trials in "ISPG - Institut fuer Studien zur Psychischen Gesundheit" are 7 trials for "All" genders.

Currently, there are NaN active trials in "ISPG - Institut fuer Studien zur Psychischen Gesundheit". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in ISPG - Institut fuer Studien zur Psychischen Gesundheit, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in ISPG - Institut fuer Studien zur Psychischen Gesundheit, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".